



General Assembly

January Session, 2011

**Committee Bill No. 5032**

LCO No. 2545

\* \_\_\_\_\_HB05032INS\_\_021811\_\_\_\_\_\*

Referred to Committee on Insurance and Real Estate

Introduced by:  
(INS)

**AN ACT REQUIRING HEALTH INSURANCE COVERAGE FOR BONE MARROW TESTING.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective January 1, 2012*) (a) Subject to the  
2 provisions of subsection (b) of this section, each individual health  
3 insurance policy providing coverage of the type specified in  
4 subdivisions (1), (2), (4), (11) and (12) of section 38a-469 of the general  
5 statutes delivered, issued for delivery, amended, renewed or  
6 continued in this state shall provide coverage for expenses arising  
7 from human leukocyte antigen testing, also referred to as  
8 histocompatibility locus antigen testing, for A, B and DR antigens for  
9 utilization in bone marrow transplantation.

10 (b) No such policy shall impose a coinsurance, copayment,  
11 deductible or other out-of-pocket expense for such testing in excess of  
12 twenty per cent of the cost for such testing per year. The provisions of  
13 this subsection shall not apply to a high deductible health plan as that  
14 term is used in subsection (f) of section 38a-493 of the general statutes.

15 (c) Such policy shall:

16 (1) Require that such testing be performed in a facility (A)  
17 accredited by the American Society for Histocompatibility and  
18 Immunogenetics, or its successor, and (B) certified under the Clinical  
19 Laboratory Improvement Act of 1967, 42 USC Section 263a, as  
20 amended from time to time; and

21 (2) Limit coverage to individuals who, at the time of such testing,  
22 complete and sign an informed consent form that also authorizes the  
23 results of the test to be used for participation in the National Marrow  
24 Donor Program.

25 (d) Such policy may limit such coverage to a lifetime maximum  
26 benefit of one testing.

27 Sec. 2. (NEW) (*Effective January 1, 2012*) (a) Subject to the provisions  
28 of subsection (b) of this section, each group health insurance policy  
29 providing coverage of the type specified in subdivisions (1), (2), (4),  
30 (11) and (12) of section 38a-469 of the general statutes delivered, issued  
31 for delivery, amended, renewed or continued in this state shall provide  
32 coverage for expenses arising from human leukocyte antigen testing,  
33 also referred to as histocompatibility locus antigen testing, for A, B and  
34 DR antigens for utilization in bone marrow transplantation.

35 (b) No such policy shall impose a coinsurance, copayment,  
36 deductible or other out-of-pocket expense for such testing in excess of  
37 twenty per cent of the cost for such testing per year. The provisions of  
38 this subsection shall not apply to a high deductible health plan as that  
39 term is used in subsection (f) of section 38a-520 of the general statutes.

40 (c) Such policy shall:

41 (1) Require that such testing be performed in a facility (A)  
42 accredited by the American Society for Histocompatibility and  
43 Immunogenetics, or its successor, and (B) certified under the Clinical  
44 Laboratory Improvement Act of 1967, 42 USC Section 263a, as  
45 amended from time to time; and

46       (2) Limit coverage to individuals who, at the time of such testing,  
47 complete and sign an informed consent form that also authorizes the  
48 results of the test to be used for participation in the National Marrow  
49 Donor Program.

50       (d) Such policy may limit such coverage to a lifetime maximum  
51 benefit of one testing.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>January 1, 2012</i>	New section
Sec. 2	<i>January 1, 2012</i>	New section

**INS**       *Joint Favorable*